PD-L1 is the most used biomarker to guide decisions regarding ICI regimens for patients with metastatic NSCLC, and it has been reported to be positively associated with a benefit from ICIs [19,20]. The gene discussed is CD274; the disease is non-small cell lung carcinoma.